KR102625645B1 - B형 간염 바이러스에 대한 백신 - Google Patents

B형 간염 바이러스에 대한 백신 Download PDF

Info

Publication number
KR102625645B1
KR102625645B1 KR1020237003896A KR20237003896A KR102625645B1 KR 102625645 B1 KR102625645 B1 KR 102625645B1 KR 1020237003896 A KR1020237003896 A KR 1020237003896A KR 20237003896 A KR20237003896 A KR 20237003896A KR 102625645 B1 KR102625645 B1 KR 102625645B1
Authority
KR
South Korea
Prior art keywords
leu
ser
pro
arg
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237003896A
Other languages
English (en)
Korean (ko)
Other versions
KR20230021771A (ko
Inventor
베르트랑 빅토르 질베르 조르쥬
칼턴 브래들리 브라운
Original Assignee
알티뮨 유케이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알티뮨 유케이 리미티드 filed Critical 알티뮨 유케이 리미티드
Publication of KR20230021771A publication Critical patent/KR20230021771A/ko
Application granted granted Critical
Publication of KR102625645B1 publication Critical patent/KR102625645B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/02Hepadnaviridae, e.g. hepatitis B virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237003896A 2012-12-24 2013-12-20 B형 간염 바이러스에 대한 백신 Active KR102625645B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1223386.2A GB201223386D0 (en) 2012-12-24 2012-12-24 Vaccine
GB1223386.2 2012-12-24
PCT/GB2013/053410 WO2014102540A1 (en) 2012-12-24 2013-12-20 Vaccines against hepatitis b virus
KR1020227003308A KR102497063B1 (ko) 2012-12-24 2013-12-20 B형 간염 바이러스에 대한 백신

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003308A Division KR102497063B1 (ko) 2012-12-24 2013-12-20 B형 간염 바이러스에 대한 백신

Publications (2)

Publication Number Publication Date
KR20230021771A KR20230021771A (ko) 2023-02-14
KR102625645B1 true KR102625645B1 (ko) 2024-01-15

Family

ID=47682590

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237003896A Active KR102625645B1 (ko) 2012-12-24 2013-12-20 B형 간염 바이러스에 대한 백신
KR1020157020103A Expired - Fee Related KR102358621B1 (ko) 2012-12-24 2013-12-20 B형 간염 바이러스에 대한 백신
KR1020227003308A Active KR102497063B1 (ko) 2012-12-24 2013-12-20 B형 간염 바이러스에 대한 백신

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020157020103A Expired - Fee Related KR102358621B1 (ko) 2012-12-24 2013-12-20 B형 간염 바이러스에 대한 백신
KR1020227003308A Active KR102497063B1 (ko) 2012-12-24 2013-12-20 B형 간염 바이러스에 대한 백신

Country Status (12)

Country Link
US (3) US10300132B2 (enExample)
EP (2) EP2935313B1 (enExample)
JP (3) JP6811014B2 (enExample)
KR (3) KR102625645B1 (enExample)
CN (2) CN104903343A (enExample)
CA (1) CA2895459A1 (enExample)
DK (1) DK2935313T3 (enExample)
EA (1) EA201591213A1 (enExample)
ES (1) ES2906110T3 (enExample)
GB (1) GB201223386D0 (enExample)
PL (1) PL2935313T3 (enExample)
WO (1) WO2014102540A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
WO2016020538A1 (en) * 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
CN106610423A (zh) * 2015-10-26 2017-05-03 复旦大学 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法
US11419927B2 (en) 2016-06-02 2022-08-23 Ultimovacs As Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
AU2017281389B2 (en) 2016-06-20 2024-02-22 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
CA3085492A1 (en) * 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
BR112020020323A2 (pt) * 2018-04-04 2021-01-05 Altimmune Inc Combinação de vacina, e, método para induzir uma resposta imune.
WO2020145901A1 (en) * 2019-01-11 2020-07-16 Agency For Science, Technology And Research Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells
WO2020255018A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
PH12022550490A1 (en) * 2019-08-29 2023-02-06 Triad Nat Security Llc Hepatitis b virus vaccines
JP2023505304A (ja) * 2019-12-07 2023-02-08 アイエスエー ファーマシューティカルズ ビー.ヴイ. B型肝炎ウイルスに関連する疾患の治療
AU2021205936A1 (en) * 2020-01-09 2022-07-21 The Wistar Institute Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same
EP4161644A2 (en) * 2020-06-08 2023-04-12 F. Hoffmann-La Roche AG Anti-hbv antibodies and methods of use
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003753A1 (en) 1991-08-26 1993-03-04 The Scripps Research Institute Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus
WO1995003777A1 (en) 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
JP2004508320A (ja) 2000-09-08 2004-03-18 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を用いるb型肝炎ウイルスに対する細胞性免疫応答の誘導
JP2007532614A (ja) 2004-04-13 2007-11-15 イミューン ターゲティング システムズ 抗原デリバリベクタ及びコンストラクト

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003753A1 (en) 1991-08-26 1993-03-04 The Scripps Research Institute Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus
WO1995003777A1 (en) 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
JP2004508320A (ja) 2000-09-08 2004-03-18 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を用いるb型肝炎ウイルスに対する細胞性免疫応答の誘導
JP2007532614A (ja) 2004-04-13 2007-11-15 イミューン ターゲティング システムズ 抗原デリバリベクタ及びコンストラクト

Also Published As

Publication number Publication date
JP7187237B2 (ja) 2022-12-12
JP6811014B2 (ja) 2021-01-13
EP2935313B1 (en) 2021-11-24
JP2019034946A (ja) 2019-03-07
KR20150098676A (ko) 2015-08-28
US20200016263A1 (en) 2020-01-16
KR102358621B1 (ko) 2022-02-03
KR20220019846A (ko) 2022-02-17
KR20230021771A (ko) 2023-02-14
JP2021098711A (ja) 2021-07-01
KR102497063B1 (ko) 2023-02-06
US10300132B2 (en) 2019-05-28
CN114028553A (zh) 2022-02-11
CA2895459A1 (en) 2014-07-03
CN104903343A (zh) 2015-09-09
WO2014102540A1 (en) 2014-07-03
US20230090379A1 (en) 2023-03-23
DK2935313T3 (da) 2022-02-28
JP7235785B2 (ja) 2023-03-08
US20160106830A1 (en) 2016-04-21
EP3995146A1 (en) 2022-05-11
EP2935313A1 (en) 2015-10-28
JP2016505589A (ja) 2016-02-25
US11918645B2 (en) 2024-03-05
US11382969B2 (en) 2022-07-12
GB201223386D0 (en) 2013-02-06
EA201591213A1 (ru) 2016-02-29
PL2935313T3 (pl) 2022-05-02
ES2906110T3 (es) 2022-04-13

Similar Documents

Publication Publication Date Title
US11918645B2 (en) Vaccines against hepatitis B virus
JP3738395B2 (ja) Hla−制限型b型肝炎ウィルスのctlエピトープ
US9562076B2 (en) Hydrophobic modified pres-derived peptides of hepatitis B virus (HBV) and their use as HBV and HDV entry inhibitors
US20160199469A1 (en) Oncology vaccine
AU2016201589B2 (en) Peptide adjuvants
HK40067424A (en) Pharmaceutical compositions comprising combination of immunogenic peptides
US20230263881A1 (en) Vaccine compositions for SARS-related coronaviruses and methods of use
BR112015015198B1 (pt) Composição farmacêutica, e, vetor de fluorcarbono

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230202

Application number text: 1020227003308

Filing date: 20220127

PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231012

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240111

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240111

End annual number: 3

Start annual number: 1

PG1601 Publication of registration